GSK PLC ADRhedged
GSKH
1 hedge funds and large institutions have $77 invested in GSK PLC ADRhedged in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
98% less capital invested
Capital invested by funds: $4.43K → $77 (-$4.36K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$76 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
JP Morgan Chase
New York
| $77 | +$76 | +1 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$4.43K | -65 | Closed |
|
GSKH Hedge Fund Activity: Q1 2026 in Review
1 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in GSK PLC ADRhedged (GSKH) for Q1 2026, worth a combined $77 — down 98% from $4.43K a quarter earlier.
Fund positioning in GSKH was balanced in Q1 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $76. The largest seller was UBS Group, exiting entirely with an estimated $4.43K sold.
- 1 institutional investor held GSK PLC ADRhedged (GSKH) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $77 of GSK PLC ADRhedged stock for Q1 2026, down 98% quarter-over-quarter.
- 1 fund opened new GSK PLC ADRhedged positions in Q1 2026 and 1 closed out, a net change of 0 holders.
- The largest GSK PLC ADRhedged buyer in Q1 2026 was JP Morgan Chase, an estimated $76 added.
- The largest GSK PLC ADRhedged seller in Q1 2026 was UBS Group, an estimated $4.43K sold.
Based on aggregated 13F filings for Q1 2026.